News & Insights
By Kimberley Ferguson, Executive Vice President, Sales & Marketing
Will we be asking our doctors for Watson by name? IBM is counting on it.
As healthcare professionals, we know that every data point presents an opportunity to learn and improve care. We want to integrate and share data. Yet often, we don’t. We’re standing at the precipice of the healthcare information technology and big data information age, with data security concerns as one of the most pressing issues in the modern healthcare-computing environment. And it’s impeding our progress.
Billions have been invested to capture and store patient data, resulting in the creation of massive quantities of healthcare data—more today than at any point in history. Yet, an estimated 80% of that data remains unstructured, and therefore, locked and inaccessible.
Through the lens of precision medicine, all disease, no matter how common, is rare disease.
The biopharmaceutical industry is under tremendous pressure to deliver more robust research methodologies, investigate new treatments, and better understand (and predict) interactive affects for those with comorbidities and concomitant treatments. Yet, at the same time, an estimated 80% of healthcare data remains unstructured, and therefore locked and inaccessible.
The search for true interoperability can be time consuming, frustrating, and more often than not, confusing. Wide claims are often made about interoperability solutions, only to later find they aren’t truly interoperable. Oversold and under- delivered may be the industry norm, but it’s not a certainty. The best way to ensure you’re pleased with your interoperability solution is to ask the right questions from the start. Consider the below a primer on the three C’s to true interoperability: care, collaboration and cost.